Pfizer, a major pharmaceutical company, saw a significant rise in shares due to its Covid vaccine during the pandemic. However, the stock has since sharply corrected, making it a potential opportunity for long-term investors. Pfizer’s stock price fell roughly 60% from its 2022 peak, presenting a possible chance for growth.

As a drug company, Pfizer faces the challenge of developing new drugs, obtaining regulatory approval, and dealing with patent cliffs as patents expire. Despite this, Pfizer has historically managed this cycle well, making it a solid healthcare stock for long-term investment. Investors may find it a good time to consider adding Pfizer to their portfolio.

Pfizer’s stock price saw a dramatic rise and fall related to the COVID-19 vaccine hype, with a peak price-to-sales ratio before plummeting back down. While revenue increased temporarily due to the pandemic, the company is now facing patent cliffs on key drugs. Investors have become more pessimistic about Pfizer’s prospects, overlooking its solid business fundamentals.

Pfizer has a long history of managing business cycles effectively, with a focus on developing new drugs to offset losses from expiring patents. Despite recent stock price volatility, Pfizer remains a strong candidate for long-term wealth creation. The company’s consistent dividend increases and current high yield make it an attractive option for investors seeking stability and potential growth.

Read more at Yahoo Finance: Is Pfizer a Millionaire Maker?